Carla J Greenbaum

List of Publications by Citations

115 papers	9,389 citations	48 h-index	96 g-index
121 ext. papers	11,314 ext. citations	10.6 avg, IF	5.68 L-index

#	Paper	IF	Citations
115	Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. *New England Journal of Medicine*, **2009**, 361, 2143-52	59.2	717
114	Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. *Diabetes Care*, **2005**, 28, 1068-76	14.6	492
113	Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. *Diabetes Care*, **2015**, 38, 1964-74	14.6	435
112	Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2011**, 378, 412-9	40	403
111	Identification of tissue-specific cell death using methylation patterns of circulating DNA. *Proceedings of the National Academy of Sciences of the United States of America*, **2016**, 113, E1826-34	11.5	350
110	Genetic variation in PTPN22 corresponds to altered function of T and B lymphocytes. *Journal of Immunology*, **2007**, 179, 4704-10	5.3	271
109	An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes. *New England Journal of Medicine*, **2019**, 381, 603-613	59.2	269
108	Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. *Lancet, The*, **2011**, 378, 319-27	40	263
107	Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs □cell function. *Diabetes*, **2012**, 61, 2340-8	0.9	234
106	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. *Lancet, The*, **2013**, 381, 1905-15	40	234
105	The effector T cells of diabetic subjects are resistant to regulation via CD4+ FOXP3+ regulatory T cells. *Journal of Immunology*, **2008**, 181, 7350-5	5.3	233
104	Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. *Diabetes*, **2013**, 62, 3766-74	0.9	222
103	Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. *Diabetes*, **2012**, 61, 2066-73	0.9	216
102	Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. *Diabetes*, **2010**, 59, 407-15	0.9	208
101	Mixed-meal tolerance test versus glucagon stimulation test for the assessment of beta-cell function in therapeutic trials in type 1 diabetes. *Diabetes Care*, **2008**, 31, 1966-71	14.6	203
100	Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. *Journal of Clinical Investigation*, **2015**, 125, 3285-96	15.9	157
99	Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. *Clinical Immunology*, **2009**, 132, 166-73	9	153

98	B-lymphocyte depletion with rituximab and β-cell function: two-year results. *Diabetes Care*, **2014**, 37, 453-9	14.6	144
97	Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. *Diabetes Care*, **2015**, 38, 476-81	14.6	132
96	Patterns of metabolic progression to type 1 diabetes in the Diabetes Prevention Trial-Type 1. *Diabetes Care*, **2006**, 29, 643-9	14.6	127
95	Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. *Diabetes Care*, **2014**, 37, 1069-75	14.6	126
94	Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet Diabetes and Endocrinology,the*, **2013**, 1, 284-94	18.1	124
93	Failure to preserve beta-cell function with mycophenolate mofetil and daclizumab combined therapy in patients with new- onset type 1 diabetes. *Diabetes Care*, **2010**, 33, 826-32	14.6	114
92	Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes. *Diabetes Care*, **2020**, 43, 5-12	14.6	111
91	Insulin resistance in type 1 diabetes. *Diabetes/Metabolism Research and Reviews*, **2002**, 18, 192-200	7.5	107
90	Recognition of posttranslationally modified GAD65 epitopes in subjects with type 1 diabetes. *Diabetes*, **2014**, 63, 3033-40	0.9	103
89	Altered B cell homeostasis is associated with type I diabetes and carriers of the PTPN22 allelic variant. *Journal of Immunology*, **2012**, 188, 487-96	5.3	99
88	GAD65-specific CD4+ T-cells with high antigen avidity are prevalent in peripheral blood of patients with type 1 diabetes. *Diabetes*, **2004**, 53, 1987-94	0.9	90
87	Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2017**, 318, 1891-1902	27.4	88
86	A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1. *Diabetes Care*, **2008**, 31, 528-33	14.6	88
85	Autoreactive T cells specific for insulin B:11-23 recognize a low-affinity peptide register in human subjects with autoimmune diabetes. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 14840-5	11.5	87
84	Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. *Journal of Immunology*, **2006**, 176, 2781-9	5.3	85
83	Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. *Diabetes*, **2002**, 51, 951-7	0.9	84
82	Type 1 Diabetes TrialNet--an international collaborative clinical trials network. *Annals of the New York Academy of Sciences*, **2008**, 1150, 14-24	6.5	81
81	Role of insulin resistance in predicting progression to type 1 diabetes. *Diabetes Care*, **2007**, 30, 2314-20	14.6	78

80	Intermolecular antigen spreading occurs during the preclinical period of human type 1 diabetes. *Journal of Immunology*, **2001**, 166, 5265-70	5.3	77
79	Fall in C-Peptide During First 4 Years From Diagnosis of Type 1 Diabetes: Variable Relation to Age, HbA1c, and Insulin Dose. *Diabetes Care*, **2016**, 39, 1664-70	14.6	76
78	Effect of rituximab on human in vivo antibody immune responses. *Journal of Allergy and Clinical Immunology*, **2011**, 128, 1295-1302.e5	11.5	76
77	Comparative study of GAD65-specific CD4+ T cells in healthy and type 1 diabetic subjects. *Journal of Autoimmunity*, **2005**, 25, 303-11	15.5	76
76	Multiple autoimmune-associated variants confer decreased IL-2R signaling in CD4+ CD25(hi) T cells of type 1 diabetic and multiple sclerosis patients. *PLoS ONE*, **2013**, 8, e83811	3.7	72
75	Zinc transporter-8 autoantibodies improve prediction of type 1 diabetes in relatives positive for the standard biochemical autoantibodies. *Diabetes Care*, **2012**, 35, 1213-8	14.6	71
74	Preservation of beta-cell function in autoantibody-positive youth with diabetes. *Diabetes Care*, **2009**, 32, 1839-44	14.6	66
73	A Type 1 Diabetes Genetic Risk Score Predicts Progression of Islet Autoimmunity and Development of Type 1 Diabetes in Individuals at Risk. *Diabetes Care*, **2018**, 41, 1887-1894	14.6	59
72	Enhanced T cell responses to IL-6 in type 1 diabetes are associated with early clinical disease and increased IL-6 receptor expression. *Science Translational Medicine*, **2016**, 8, 356ra119	17.5	57
71	First Genome-Wide Association Study of Latent Autoimmune Diabetes in Adults Reveals Novel Insights Linking Immune and Metabolic Diabetes. *Diabetes Care*, **2018**, 41, 2396-2403	14.6	57
70	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves Cell Function and Improves HbA in New-Onset Type 1 Diabetes. *Diabetes Care*, **2018**, 41, 1917-1925	14.6	56
69	Defining pathways for development of disease-modifying therapies in children with type 1 diabetes: a consensus report. *Diabetes Care*, **2015**, 38, 1975-85	14.6	52
68	Molecular signatures differentiate immune states in type 1 diabetic families. *Diabetes*, **2014**, 63, 3960-73	0.9	48
67	Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. *Diabetes Care*, **2019**, 42, 258-264	14.6	48
66	CD4+ T cells from type 1 diabetic and healthy subjects exhibit different thresholds of activation to a naturally processed proinsulin epitope. *Journal of Autoimmunity*, **2008**, 31, 30-41	15.5	46
65	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data. *Diabetes*, **2019**, 68, 1267-1276	0.9	45
64	Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1. *Diabetes Care*, **2009**, 32, 1603-7	14.6	45
63	ISPAD Clinical Practice Consensus Guidelines 2018: Stages of type 1 diabetes in children and adolescents. *Pediatric Diabetes*, **2018**, 19 Suppl 27, 20-27	3.6	44

62	Islet cell antibody-positive relatives with human leukocyte antigen DQA1*0102, DQB1*0602: identification by the Diabetes Prevention Trial-type 1. *Journal of Clinical Endocrinology and Metabolism*, **2000**, 85, 1255-60	5.6	40
61	Understanding and preventing type 1 diabetes through the unique working model of TrialNet. *Diabetologia*, **2017**, 60, 2139-2147	10.3	39
60	HLA-DRB1*15:01-DQA1*01:02-DQB1*06:02 Haplotype Protects Autoantibody-Positive Relatives From Type 1 Diabetes Throughout the Stages of Disease Progression. *Diabetes*, **2016**, 65, 1109-19	0.9	37
59	Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. *Science Translational Medicine*, **2021**, 13,	17.5	37
58	A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history. *Diabetes Care*, **2015**, 38, 271-6	14.6	36
57	High residual C-peptide likely contributes to glycemic control in type 1 diabetes. *Journal of Clinical Investigation*, **2020**, 130, 1850-1862	15.9	36
56	Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis. *Diabetologia*, **2019**, 62, 655-664	10.3	35
55	Single-Cell RNA Sequencing Reveals Expanded Clones of Islet Antigen-Reactive CD4 T Cells in Peripheral Blood of Subjects with Type 1 Diabetes. *Journal of Immunology*, **2017**, 199, 323-335	5.3	34
54	Modifying Enzymes Are Elicited by ER Stress, Generating Epitopes That Are Selectively Recognized by CD4 T Cells in Patients With Type 1 Diabetes. *Diabetes*, **2018**, 67, 1356-1368	0.9	34
53	Through the fog: recent clinical trials to preserve cell function in type 1 diabetes. *Diabetes*, **2012**, 61, 1323-30	0.9	33
52	CD4+ T cells recognize diverse epitopes within GAD65: implications for repertoire development and diabetes monitoring. *Immunology*, **2013**, 138, 269-79	7.8	31
51	Type 1 Diabetes TrialNet: A Multifaceted Approach to Bringing Disease-Modifying Therapy to Clinical Use in Type 1 Diabetes. *Diabetes Care*, **2018**, 41, 653-661	14.6	30
50	The relationship between BMI and insulin resistance and progression from single to multiple autoantibody positivity and type 1 diabetes among TrialNet Pathway to Prevention participants. *Diabetologia*, **2016**, 59, 1186-95	10.3	29
49	Assessment of CD4+ T cell responses to glutamic acid decarboxylase 65 using DQ8 tetramers reveals a pathogenic role of GAD65 121-140 and GAD65 250-266 in T1D development. *PLoS ONE*, **2014**, 9, e112882	3.7	28
48	Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). *Diabetes*, **2010**, 59, 2386-9	0.9	28
47	Fine-mapping, trans-ancestral and genomic analyses identify causal variants, cells, genes and drug targets for type 1 diabetes. *Nature Genetics*, **2021**, 53, 962-971	36.3	28
46	Specific human leukocyte antigen DQ influence on expression of antiislet autoantibodies and progression to type 1 diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2006**, 91, 1705-13	5.6	27
45	Measurement of Pro-Islet Amyloid Polypeptide (1-48) in Diabetes and Islet Transplants. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 2595-2603	5.6	24

44	B lymphocyte alterations accompany abatacept resistance in new-onset type 1 diabetes. *JCI Insight*, **2019**, 4,	9.9	24
43	Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice. *Drugs*, **2019**, 79, 43-61	12.1	24
42	Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience. *Diabetes*, **2018**, 67, 1216-1225	0.9	24
41	Elevated T cell levels in peripheral blood predict poor clinical response following rituximab treatment in new-onset type 1 diabetes. *Genes and Immunity*, **2019**, 20, 293-307	4.4	23
40	Cell type-specific immune phenotypes predict loss of insulin secretion in new-onset type 1 diabetes. *JCI Insight*, **2019**, 4,	9.9	21
39	Making progress: preserving beta cells in type 1 diabetes. *Annals of the New York Academy of Sciences*, **2011**, 1243, 119-34	6.5	20
38	Innate immune activity as a predictor of persistent insulin secretion and association with responsiveness to CTLA4-Ig treatment in recent-onset type 1 diabetes. *Diabetologia*, **2018**, 61, 2356-2370	10.3	20
37	Heterogeneity in recent-onset type 1 diabetes - a clinical trial perspective. *Diabetes/Metabolism Research and Reviews*, **2015**, 31, 588-94	7.5	19
36	High Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1 Associate With Protection From Vascular Complications in People With Long-standing Type 1 Diabetes. *Diabetes Care*, **2020**, 43, 178-186	14.6	19
35	Abnormalities in proinsulin processing in islets from individuals with longstanding T1D. *Translational Research*, **2019**, 213, 90-99	11	18
34	Hybrid Insulin Peptides Are Recognized by Human T Cells in the Context of DRB1*04:01. *Diabetes*, **2020**, 69, 1492-1502	0.9	17
33	C-Peptide Levels in Subjects Followed Longitudinally Before and After Type 1 Diabetes Diagnosis in TrialNet. *Diabetes Care*, **2020**, 43, 1836-1842	14.6	17
32	Genetic Discrimination Between LADA and Childhood-Onset Type 1 Diabetes Within the MHC. *Diabetes Care*, **2020**, 43, 418-425	14.6	15
31	Dynamic Immune Phenotypes of B and T Helper Cells Mark Distinct Stages of T1D Progression. *Diabetes*, **2019**, 68, 1240-1250	0.9	14
30	Antigen-Specific T Cell Analysis Reveals That Active Immune Responses to Cell Antigens Are Focused on a Unique Set of Epitopes. *Journal of Immunology*, **2017**, 199, 91-96	5.3	12
29	Assessment of Cell Mass and Function by AIRmax and Intravenous Glucose in High-Risk Subjects for Type 1 Diabetes. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 4428-4434	5.6	12
28	Disease modifying therapies in type 1 diabetes: Where have we been, and where are we going?. *Pharmacological Research*, **2015**, 98, 3-8	10.2	12
27	Multiplexing DNA methylation markers to detect circulating cell-free DNA derived from human pancreatic cells. *JCI Insight*, **2020**, 5,	9.9	12

26	Genetics Coming of Age in Type 1 Diabetes. *Diabetes Care*, **2019**, 42, 189-191	14.6	10
25	Metabolic tests to determine risk for type 1 diabetes in clinical trials. *Diabetes/Metabolism Research and Reviews*, **2011**, 27, 584-9	7.5	10
24	Who Is Enrolling? The Path to Monitoring in Type 1 Diabetes TrialNet's Pathway to Prevention. *Diabetes Care*, **2019**, 42, 2228-2236	14.6	10
23	Analysis of pancreatic beta cell specific CD4+ T cells reveals a predominance of proinsulin specific cells. *Cellular Immunology*, **2019**, 335, 68-75	4.4	9
22	DRB4*01:01 Has a Distinct Motif and Presents a Proinsulin Epitope That Is Recognized in Subjects with Type 1 Diabetes. *Journal of Immunology*, **2018**, 201, 3524-3533	5.3	9
21	The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months. *Diabetes Care*, **2015**, 38, 940-2	14.6	8
20	Uncovering Pathways to Personalized Therapies in Type 1 Diabetes. *Diabetes*, **2021**, 70, 831-841	0.9	8
19	Sensitive detection of multiple islet autoantibodies in type 1 diabetes using small sample volumes by agglutination-PCR. *PLoS ONE*, **2020**, 15, e0242049	3.7	7
18	Advances in Type 1 Diabetes Prediction Using Islet Autoantibodies: Beyond a Simple Count. *Endocrine Reviews*, **2021**, 42, 584-604	27.2	7
17	Autoantibodies Directed Toward a Novel IA-2 Variant Protein Enhance Prediction of Type 1 Diabetes. *Diabetes*, **2019**, 68, 1819-1829	0.9	6
16	Systematic Assessment of Immune Marker Variation in Type 1 Diabetes: A Prospective Longitudinal Study. *Frontiers in Immunology*, **2019**, 10, 2023	8.4	6
15	Insulin is necessary but not sufficient: changing the therapeutic paradigm in type 1 diabetes. *F1000Research*, **2020**, 9,	3.6	6
14	Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals. *Diabetes Care*, **2020**, 43, 913-917	14.6	6
13	Pancreatic islet reserve in type 1 diabetes. *Annals of the New York Academy of Sciences*, **2021**, 1495, 40-54	6.5	6
12	Attenuated IL-2R signaling in CD4 memory T cells of T1D subjects is intrinsic and dependent on activation state. *Clinical Immunology*, **2017**, 181, 67-74	9	5
11	IL-6 receptor blockade does not slow β cell loss in new-onset type 1 diabetes. *JCI Insight*, **2021**, 6,	9.9	4
10	Screening for Type 1 Diabetes in the General Population: A Status Report and Perspective.. *Diabetes*, **2022**, 71, 610-623	0.9	3
9	Stacking the Deck: Studies of Patients with Multiple Autoimmune Diseases Propelled Our Understanding of Type 1 Diabetes as an Autoimmune Disease. *Journal of Immunology*, **2017**, 199, 3011-3013	5.3	2

8	Response to Comment on Sims et al. Proinsulin Secretion Is a Persistent Feature of Type 1 Diabetes. Diabetes Care 2019;42:258-264. *Diabetes Care*, **2019**, 42, e85-e86	14.6	2
7	Acute Hyperinsulinemia Alters Bone Turnover in Women and Men With Type 1 Diabetes. *JBMR Plus*, **2020**, 4, e10389	3.9	2
6	Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity.. *Science Translational Medicine*, **2022**, 14, eabi4888	17.5	1
5	Response to Comment on So et al. Autoantibody Reversion: Changing Risk Categories in Multiple-Autoantibody-Positive Individuals. Diabetes Care 2020;43:913-917. *Diabetes Care*, **2020**, 43, e103-e104	14.6	1
4	A Key to T1D Prevention: Screening and Monitoring Relatives as Part of Clinical Care. *Diabetes*, **2021**, 70, 1029-1037	0.9	1
3	Characterising the age-dependent effects of risk factors on type 1 diabetes progression.. *Diabetologia*, **2022**, 65, 684	10.3	0
2	Citrullination of glucokinase is linked to autoimmune diabetes.. *Nature Communications*, **2022**, 13, 1870	17.4	0
1	Disease-modifying Therapies for the Prevention of Type 1 Diabetes. *US Endocrinology*, **2019**, 15, 15	0.3	